美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

百濟神州

353.37

+7.302.11%

成交量：11.94萬

成交額：4,204.63萬

市值：420.51億

市盈率：679.04

高：356.63

開：346.07

低：346.00

收：346.07

52周最高：385.22

52周最低：196.45

股本：1.19億

流通股本：7,564.19萬

量比：0.89

換手率：0.16%

股息：- -

股息率：- -

每股收益(TTM):0.5204

每股收益(LYR):-6.1240

淨資產收益率：1.81%

總資產收益率：1.69%

市淨率：10.18

市盈率(LYR):-57.70

資料載入中...

總覽公司新聞資訊公告

百濟神州(06160)授出涉及2.1萬股美國存托股份的受限制股份單位

智通财经网

從信達生物、恒瑞醫藥和百濟神州，看Biopharma的估值區間

中國上市、全球首發！百濟神州這一創新藥開啓血液腫瘤治療新篇章

中金港股通與恒指調整預覽：紫金黃金國際(02259)等有望納入恒指預計44只公司有望入港股通

《大行》中金料紫金國際、百濟、財險及康方生物或「染藍」渣打可能「遞補」恒生銀行位置

阿斯达克财经

JPM2026 | 百濟神州：駛入全球研發快車道

医药魔方Info

百濟神州(06160.HK)高開逾3%

每日经济新闻

港股異動 | 百濟神州(06160)高開逾3% 宣佈百悦達®在中國商業化上市首批藥品將覆蓋全國70個城市

百濟神州盤中異動臨近收盤股價大漲5.34%報351.83美元

醫藥生物行業周報：聚焦腦機接口與小核酸藥物 JPM盛會前奏下醫療佈局新浪潮

东方财富证券股...

百濟神州：伯恩斯坦上調評級至跑贏大市，目標價升至414美元

百濟神州(06160)授出合共5.33萬股美國存托股份受限制股份單位

百濟神州新型BCL2抑制劑百悦達（索托克拉片）在中國獲得上市許可

老虎资讯综合

又出血液腫瘤新藥！百濟神州股價微跌，「創新藥一哥」能再造爆款？

重磅，百濟神州又一款1類新藥迎來新進展

北京药研汇

千億出海潮：中國創新藥企駛入全球深水區

從量變到質變，政策協同、技術爆發與產業重構的三重躍遷

百濟神州盤中異動早盤急速上漲5.44%報327.95美元

百濟神州BG - C0902啓動Ⅰ期臨牀適應症為晚期實體瘤

百濟神州BCL-2抑制劑「索托克拉」獲批上市

医药魔方Info

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":353.3725,"timestamp":1771358602860,"preClose":346.07,"halted":0,"volume":119388,"delay":0,"changeRate":0.021101222296067295,"floatShares":75641900,"shares":119000000,"eps":0.5204,"marketStatus":"交易中","change":7.3025,"latestTime":"02-17 15:03:27 EST","open":346.07,"high":356.63,"low":346,"amount":42046304.616000004,"amplitude":0.030716,"askPrice":353.81,"askSize":198,"bidPrice":352.77,"bidSize":40,"shortable":3,"etf":0,"ttmEps":0.5204,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1771362000000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":346.07,"preHourTrading":{"tag":"盘前","latestPrice":345.93,"preClose":346.07,"latestTime":"06:50 EST","volume":1,"amount":345.93,"timestamp":1771329039095,"change":-0.14,"changeRate":-0.000405,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":346.07,"preClose":346.07,"latestTime":"16:10 EST","volume":1467,"amount":507678.62,"timestamp":1771017004872,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.888747,"impliedVol":0.4846,"impliedVolPercentile":0.7331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75641900,"roa":"1.69%","roe":"1.81%","lyrEps":-6.124009,"volumeRatio":0.888747,"shares":119000000,"dividePrice":0,"high":356.63,"amplitude":0.030716,"preClose":346.07,"low":346,"week52Low":196.45,"pbRate":"10.18","psRate":"8.46","week52High":385.22,"institutionHeld":0,"latestPrice":353.3725,"committee":-0.663866,"eps":0.5204,"divideRate":0,"volume":119388,"delay":0,"ttmEps":0.5204,"open":346.07,"prevYearClose":303.81,"prevWeekClose":346.07,"prevMonthClose":340.38,"prevQuarterClose":303.81,"fiveDayClose":348.85,"twentyDayClose":338.19,"sixtyDayClose":363.92,"earningDate":1772035200000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2026-02-26","symbol":"ONC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":1.6,"defaultRemindTime":1772139600000,"name":null,"time":"盤後","dateTimestamp":1772082000000,"actualEps":null},{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2917,"buy":0.6667,"hold":0,"sell":0.0417,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":24,"updateTime":1768194000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-02-13","current":680.245965,"percent":0.95814,"low":-217.585346,"twenty":-84.275105,"median":-39.916618,"eighty":-20.627155,"high":609.337035,"avg":22.800715,"sd":227.88289,"marketCap":38334124614},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-09","current":517.162439,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"marketCap":35451485198},{"date":"2026-01-16","current":546.090088,"twenty":-85.828543,"median":-40.382553,"eighty":-21.503627,"marketCap":37434475537},{"date":"2026-01-23","current":546.929506,"twenty":-85.639801,"median":-40.307741,"eighty":-21.22036,"marketCap":37492017667},{"date":"2026-01-30","current":564.993144,"twenty":-85.550958,"median":-40.153659,"eighty":-20.966373,"marketCap":38730280050},{"date":"2026-02-06","current":560.150346,"twenty":-85.195011,"median":-40.102874,"eighty":-20.825389,"marketCap":38398306221},{"date":"2026-02-13","current":559.214072,"twenty":-84.275105,"median":-39.916618,"eighty":-20.627155,"marketCap":38334124614}],"updateTime":1771353125380},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607018875","title":"百濟神州(06160)授出涉及2.1萬股美國存托股份的受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2607018875","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607018875?lang=zh_tw&edition=fundamental","pubTime":"2026-01-30 16:54","pubTimestamp":1769763247,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年1月23 日，董事会薪酬委员会根据2016期权及激励计划的条款向二百四十六名承授人授出涉及合共2.1万股美国存托股份的受限制股份单位。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","LU0588546209.SGD","LU1770034418.SGD","06160","LU0307460666.USD","LU1969619763.USD","LU1719994722.HKD","BK4526","LU1251922891.USD","ONC","BK1588","BK4585","BK1161","BK4139","BK0239","688235","LU1303224171.USD","LU2328871848.SGD","BK1500"],"gpt_icon":0},{"id":"2607801831","title":"從信達生物、恒瑞醫藥和百濟神州，看Biopharma的估值區間","url":"https://stock-news.laohu8.com/highlight/detail?id=2607801831","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607801831?lang=zh_tw&edition=fundamental","pubTime":"2026-01-30 16:47","pubTimestamp":1769762820,"startTime":"0","endTime":"0","summary":"也就是说Biotech和Biopharma的估值存在较大差异。　　为了进一步厘清这种差异，我们选取了信达生物、恒瑞医药和百济神州等生物制药企业，以便观察一下Biopharma的市值和营业收入规模、研发实力的关系。即，信达生物要成为Biopharma的营收至少要达到60亿的水平。　　恒瑞医药作为国内创新药龙头，其经营业绩、研发管线和市值波动的关系可以给其他Biopharma的估值参考。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-01-30/doc-inhkaqpf6970466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","LU2097828557.USD","LU0359201612.USD","LU2097828714.EUR","LU2580892862.HKD","BK1589","BK1191","LU0455707207.USD","LU2097828631.EUR","01276","06160","BK1500","HK0000165453.HKD","LU2488822045.USD","BK0012","LU1770034418.SGD","LU2580892789.USD","LU1064131003.USD","LU1820825898.SGD","LU0588546209.SGD","LU1997245094.SGD","BK0183","LU1255011170.USD","LU1023057109.AUD","BK1588","LU2543165471.USD","BK0028","BK0188","BK0060","LU1303224171.USD","01801","BK4526","LU1781817850.SGD","LU1064130708.USD","LU2328871848.SGD","LU1580142542.USD","ONC","LU1997245177.USD","600276","LU1328615791.USD","688235","LU2289578879.USD","LU1719994722.HKD","LU0359202008.SGD","LU1251922891.USD","LU1655091616.SGD","BK4585","LU2097828805.USD","LU0405327148.USD","BK0196"],"gpt_icon":0},{"id":"2606979167","title":"中國上市、全球首發！百濟神州這一創新藥開啓血液腫瘤治療新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2606979167","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606979167?lang=zh_tw&edition=fundamental","pubTime":"2026-01-28 17:17","pubTimestamp":1769591825,"startTime":"0","endTime":"0","summary":"百济神州新型BCL2抑制剂索托克拉（百悦达）中国上市会暨全球首发盛典日前举行。会上，众多专家共同就国内慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）以及套细胞淋巴瘤（MCL）的诊疗现状、治疗策略及创新诊疗格局展开分享与讨论，以期推动创新药物更好地造福国内患者。近年来，我国血液肿瘤的防治依然面临严峻挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601283633690762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1251922891.USD","BK4139","BK1161","688235","159992","LU1969619763.USD","ONC","06978","LU0588546209.SGD","BK4585","LU1719994722.HKD","BK1500","06078","BK1588","LU0737861772.HKD","LU1303224171.USD","BK4526","LU2488822045.USD","LU1770034418.SGD","BK1209","BK1574","LU0307460666.USD","LU2328871848.SGD","BK0239","LU0329678337.USD","BK1583","LU0329678170.USD","06160"],"gpt_icon":0},{"id":"2604900915","title":"中金港股通與恒指調整預覽：紫金黃金國際(02259)等有望納入恒指 預計44只公司有望入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2604900915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604900915?lang=zh_tw&edition=fundamental","pubTime":"2026-01-19 14:03","pubTimestamp":1768802591,"startTime":"0","endTime":"0","summary":"考虑到恒生指数编算细则中明确指出，恒指将保留至少20只被认定为香港公司的成分股，此数目至少每两年检讨一次，不排除此次会“递补”其他香港公司进入恒生指数的可能。港股通调整：预计44只有望入通；25只或被移出此次也适逢恒生综合指数的年度审议。此外，部分公司预计分别将于1月28日与2月10日从港交所退市，届时也将被移出港股通交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["513600","BK1198","02259","LU2213484517.USD","02328","601601","BK4614","688235","YUMC","09987","MCHmain","06160","LU0593848301.USD","09926","SGXZ62798434.SGD","HK0000500386.USD","ONC","HHImain","02833","HK0000252152.HKD","HK0000252160.HKD","06181","SGXZ86797644.SGD","LU2543165471.USD","02601"],"gpt_icon":1},{"id":"2604904389","title":"《大行》中金料紫金國際、百濟、財險及康方生物或「染藍」 渣打可能「遞補」恒生銀行位置","url":"https://stock-news.laohu8.com/highlight/detail?id=2604904389","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604904389?lang=zh_tw&edition=fundamental","pubTime":"2026-01-19 11:33","pubTimestamp":1768793580,"startTime":"0","endTime":"0","summary":"考虑到恒生指数编算细则中明确指出，恒指将保留至少20只被认定为香港公司的成分股，此数目至少每两年检讨一次，不排除此次会“递补”其他香港公司进入恒生指数的可能。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1496999/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1496999/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01972","LU2476274720.SGD","03143","688235","LU0211977185.USD","00083","LU1720050803.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0417516571.SGD","BK1572","02328","LU0348767384.USD","LU1961090484.USD","IE00B543WZ88.USD","LU2778985437.USD","00011","LU0348784397.USD","601601","02259","LU1794554557.SGD","BK1574","LU0417516738.SGD","02601","LU2399975544.HKD","BK1619","ONC","LU0348783233.USD","BK1521","SNLAY","STAN.UK","LU0607220059.USD","LU0149534421.HKD","BK1161","80011","LU0348766576.USD","LU0561508036.HKD","LU1981816686.USD","LU0348827113.USD","06160","LU2476274308.USD","BK1231","LU0348735423.USD","YUMC","09987","02888","06181","BK1601","SCBFF","LU0540923850.HKD","SG9999000327.SGD","HSNGY","LU2488822045.USD","09926","IE00BPRC5H50.USD","LU0417516902.SGD","LU0348825331.USD","SG9999001689.USD"],"gpt_icon":1},{"id":"2603616336","title":"JPM2026 | 百濟神州：駛入全球研發快車道","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616336","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616336?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 16:52","pubTimestamp":1768380775,"startTime":"0","endTime":"0","summary":"1月13日，在JPM大会上，百济神州以其在肿瘤领域的深度布局、清晰的管线战略和独特的全球研发体系，向投资者展示了一家深耕创新、立足全球的药企如何在国际舞台上持续扩大影响力。2026年，百济神州的核心血液肿瘤产品线也将迎来多个重要里程碑：泽布替尼用于一线套细胞淋巴瘤的III期MANGROVE研究数据即将公布；索托克拉在美国首个适应症的批准……更多研发事件的催化，也让百济神州驶入全球研发的快车道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114165822a4c28642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114165822a4c28642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK4585","BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2603576836","title":"百濟神州(06160.HK)高開逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576836","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576836?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 09:36","pubTimestamp":1768354599,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州(06160.HK)高开逾3%，截至发稿涨3.33%，报210.8港元，成交额1678.72万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143618443468.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143618443468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4585","BK4139","BK1500","LU1969619763.USD","BK1583","LU0307460666.USD","LU0588546209.SGD","ONC","LU1251922891.USD","LU1770034418.SGD","LU1719994722.HKD","688235","BK1588","BK1161","BK4526","06160","LU2328871848.SGD","LU1303224171.USD"],"gpt_icon":0},{"id":"2603652978","title":"港股異動 | 百濟神州(06160)高開逾3% 宣佈百悦達®在中國商業化上市 首批藥品將覆蓋全國70個城市","url":"https://stock-news.laohu8.com/highlight/detail?id=2603652978","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603652978?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 09:30","pubTimestamp":1768354233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州高开逾3%，截至发稿，涨3.33%，报210.8港元，成交额1678.72万港元。消息面上，1月14日，据百济神州官微消息，公司宣布其自主研发的1类新药新型BCL2抑制剂百悦达已于1月13日启动供应，首批药品将覆盖全国70个城市。研究结果证实，在经治CLL/SLL及R/R MCL患者中，索托克拉显示出具有临床意义的缓解获益，同时整体耐受性与安全性良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","BK4526","BK4139","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","LU0588546209.SGD","688235","LU1251922891.USD","BK0239","LU1719994722.HKD","BK1161","06160","BK1583","BK4585","BK1500","BK1588","LU1770034418.SGD","LU1303224171.USD"],"gpt_icon":0},{"id":"2603616871","title":"百濟神州盤中異動 臨近收盤股價大漲5.34%報351.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616871","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616871?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 04:54","pubTimestamp":1768337695,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日04时54分，百济神州股票出现异动，股价大幅上涨5.34%。截至发稿，该股报351.83美元/股，成交量29.9905万股，换手率0.27%，振幅4.40%。百济神州股票所在的生物技术行业中，整体跌幅为0.10%。百济神州有自己的团队进行全球临床试验。截至2024年，其核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的60%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011404545597a1ab33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011404545597a1ab33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139","BK4585"],"gpt_icon":0},{"id":"2603308697","title":"醫藥生物行業周報：聚焦腦機接口與小核酸藥物 JPM盛會前奏下醫療佈局新浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2603308697","media":"东方财富证券股...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603308697?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 00:00","pubTimestamp":1768320000,"startTime":"0","endTime":"0","summary":"本周港股116 支医药生物个股中，104 支上涨，占比89.66%。脑机接口建议关注诚益通、伟思医疗、麦澜德等。本周，小核酸创新药优质企业瑞博生物-B 上市，二级市场表现火热。第44 届摩根大通医疗健康年会将于当地时间2026 年1月 12 日-15 日在美国旧金山盛大举办。根据JPM 大会官网已公布的日程，有超 20 家中国公司将出席本届会议并发表演讲。关注会议公布重磅研发进展数据，建议关注百济神州、恒瑞医药、三生制药等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114184732a4c2efbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114184732a4c2efbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02192","06127","06160","ONC","BK1141","02228","BK1617"],"gpt_icon":1},{"id":"1155268538","title":"百濟神州：伯恩斯坦上調評級至跑贏大市，目標價升至414美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155268538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155268538?lang=zh_tw&edition=fundamental","pubTime":"2026-01-12 19:21","pubTimestamp":1768216910,"startTime":"0","endTime":"0","summary":"伯恩斯坦研究机构宣布，将百济神州的投资评级从\"与大市同步\"提升至\"跑赢大市\"，同时将其目标股价从362美元大幅上调至414美元。这一调整反映了该机构对百济神州未来发展前景的积极预期。\n此次评级上调基于对公司核心业务增长潜力的重新评估，目标价的上调幅度达到14.4%，显示出分析师对该公司价值的认可。伯恩斯坦认为，百济神州在创新药物研发和商业化方面展现出的优势，有望推动其业绩实现超预期表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4526","ONC","BK0239","688235"],"gpt_icon":0},{"id":"2601787308","title":"百濟神州(06160)授出合共5.33萬股美國存托股份受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2601787308","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601787308?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 16:49","pubTimestamp":1767775792,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年12月31日，董事会及╱或董事会薪酬委员会根据2016期权及激励计划的条款授予155名承授人合共5.33万股美国存托股份受限制股份单位。该等受限制股份单位相当于69.32万股股份，约占本公告之日公司发行股份总数的0.04%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1251922891.USD","BK4139","BK1161","688235","ONC","LU1969619763.USD","LU0588546209.SGD","BK4585","LU1719994722.HKD","BK1500","BK1588","LU1303224171.USD","BK4526","LU1770034418.SGD","LU0307460666.USD","LU2328871848.SGD","BK0239","BK1583","06160"],"gpt_icon":0},{"id":"1170001608","title":"百濟神州新型BCL2抑制劑百悦達（索托克拉片）在中國獲得上市許可","url":"https://stock-news.laohu8.com/highlight/detail?id=1170001608","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170001608?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 19:02","pubTimestamp":1767697320,"startTime":"0","endTime":"0","summary":"1月6日，$百济神州$宣布，其自研的1类新药新型BCL2抑制剂百悦达获得国家药品监督管理局附条件批准，用于治疗既往接受过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤成人患者，以及既往接受过至少两种系统性治疗的复发或难治性套细胞淋巴瘤成人患者。基于此次获批，索托克拉将为已接受过BTK抑制剂治疗的CLL/SLL患者带来新的治疗选择，更使其成为国内首款且唯一可用于治疗MCL的BCL2抑制剂。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州新型BCL2抑制剂百悦达（索托克拉片）在中国获得上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4526","LU2328871848.SGD","BK1583","BK0239","LU1770034418.SGD","BK1500","LU0588546209.SGD","BK1588","LU1969619763.USD","BK4139","ONC","06160","LU1251922891.USD","LU0307460666.USD","LU1303224171.USD","688235","BK1161","LU1719994722.HKD"],"gpt_icon":0},{"id":"2601889690","title":"又出血液腫瘤新藥！百濟神州股價微跌，「創新藥一哥」能再造爆款？","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889690","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889690?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 18:29","pubTimestamp":1767695361,"startTime":"0","endTime":"0","summary":"血液恶性肿瘤患者迎来新药。1月5日，国家药品监督管理局官网显示，国内“创新药一哥”百济神州-U（688235.SH）的BCL-2（B细胞淋巴瘤-2）抑制剂索托克拉片双适应证获批上市。上述两项适应证分别为用于治疗既往接受过治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）成人患者；用于治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤（MCL）成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610323958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1303224171.USD","BK4139","BK0239","BK4526","BK1161","06160","BK1500","BK1574","06978","159992","LU1719994722.HKD","ONC","LU1251922891.USD","LU0307460666.USD","LU2328871848.SGD","LU1969619763.USD","BK1588","BK1583","LU0588546209.SGD","BK4585","688235","LU1770034418.SGD"],"gpt_icon":0},{"id":"2601917854","title":"重磅，百濟神州又一款1類新藥迎來新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2601917854","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601917854?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 08:01","pubTimestamp":1767657678,"startTime":"0","endTime":"0","summary":"特应性皮炎，这一慢性、复发性、炎症性皮肤病，近年来在全球范围内发病率持续上升，给患者的生活质量带来了严重影响。BGB-45035是百济神州开发的一款IRAK4 CDAC，正被研究用于治疗各类自身免疫性疾病。据报道，该药物具有潜力诱导更深、更快的IRAK4降解，并且细胞因子抑制作用更强，是百济神州在自有CDAC平台上研发的第二款靶向降解剂。IRAK4作为先天免疫关键靶点，近年来受到多家药企关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106081138a6f7b13c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","BK4585","ONC","06160"],"gpt_icon":0},{"id":"2601854186","title":"千億出海潮：中國創新藥企駛入全球深水區","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854186?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK4585","BMS","CXO","ONC","BK4526","02509","01541","01801","06160","01167","BK4139"],"gpt_icon":0},{"id":"2601585325","title":"從量變到質變，政策協同、技術爆發與產業重構的三重躍遷","url":"https://stock-news.laohu8.com/highlight/detail?id=2601585325","media":"新快报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601585325?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 06:58","pubTimestamp":1767653908,"startTime":"0","endTime":"0","summary":"2025年医药健康盘点2025年，中国医药健康领域迎来从“量变”到“质变”的关键跃升，是政策、技术与产业协同成效。同期，诺和诺德口服司美格鲁肽获FDA批准用于减重，成为全球首个口服GLP-1减重药。资本与研发加速布局凸显赛道热度，印证GLP-1已成为代谢疾病核心资产。但同时，超10家企业申报司美格鲁肽生物类似药，同质化竞争风险加剧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106070629a6f781ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106070629a6f781ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1161","AZN","06978","02359","03696","01801","ONC","BK1574"],"gpt_icon":1},{"id":"2601854164","title":"百濟神州盤中異動 早盤急速上漲5.44%報327.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854164?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 22:31","pubTimestamp":1767623486,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时31分，百济神州股票出现波动，股价急速上涨5.44%。截至发稿，该股报327.95美元/股，成交量2.6425万股，换手率0.02%，振幅2.00%。百济神州股票所在的生物技术行业中，整体跌幅为0.32%。百济神州有自己的团队进行全球临床试验。截至2024年，其核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的60%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105223126a49f633b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139","BK4585"],"gpt_icon":0},{"id":"2601854118","title":"百濟神州BG - C0902啓動Ⅰ期臨牀 適應症為晚期實體瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854118","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854118?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 18:30","pubTimestamp":1767609000,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，广州百济神州生物制药有限公司的一项探索靶向 EGFR×MET 的抗体偶联药物 BG - C0902 单药治疗和与其他治疗药物联合用药治疗晚期实体瘤患者的安全性、耐受性、药代动力学、药效学和初步抗肿瘤活性的1a/1b 期研究已启动。BG - C0902 为生物制品，适应症为晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105183358a6f59bce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","LU0385154629.USD","LU0251142724.SGD","LU2211817866.USD","LU0742534661.SGD","ONC","BK4585","LU0471298777.SGD","BK4139","BK4189","LU0048573561.USD","LU0251131958.USD","LU2360106947.USD","LU0471298694.HKD","BK4588","BG"],"gpt_icon":0},{"id":"2601800005","title":"百濟神州BCL-2抑制劑「索托克拉」獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800005","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601800005?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 18:19","pubTimestamp":1767608340,"startTime":"0","endTime":"0","summary":"1 月 5日，NMPA 官网显示，百济神州BCL-2抑制剂“索托克拉”两项适应症中国获批上市，适用于治疗既往接受过治疗的慢性淋巴细胞白血病/ 小淋巴细胞淋巴瘤成人患者，以及治疗既往接受过抗CD20治疗和BTKi治疗的套细胞淋巴瘤成人患者。索托克拉是百济神州开发的一款强效、高选择性BCL-2抑制剂，其设计旨在产生更深、更持久的靶点抑制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-01-05/doc-inhfhavn6767115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1770034418.SGD","LU2328871848.SGD","LU1251922891.USD","BK0239","BK4526","BK1583","ONC","BK1588","06160","BK4139","LU0307460666.USD","BK1161","BK4585","LU1969619763.USD","LU0588546209.SGD","BK1500","LU1303224171.USD","688235","LU1719994722.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":194,"code":"91000000","status":"200"}]}}